A Reversal for bluebird bio Inc (BLUE) Is Not Near. The Stock Reaches 52-Week High Today

November 21, 2017 - By Darrin Black

Investors sentiment increased to 1.68 in 2017 Q2. Its up 0.68, from 1 in 2017Q1. It is positive, as 21 investors sold bluebird bio Inc shares while 53 reduced holdings. 50 funds opened positions while 74 raised stakes. 47.91 million shares or 5.30% more from 45.50 million shares in 2017Q1 were reported.
Voya Investment Mgmt Limited Co owns 217,398 shares. 3,250 were reported by Teacher Retirement Systems Of Texas. Public Employees Retirement Association Of Colorado stated it has 7,118 shares or 0.01% of all its holdings. First Personal Fincl Services owns 205 shares. Geneva Ltd Liability owns 3,205 shares. Federated Invsts Inc Pa has invested 0.01% in bluebird bio Inc (NASDAQ:BLUE). Strs Ohio accumulated 7,400 shares. Teachers Retirement Of The State Of Kentucky reported 32,587 shares. Wellington Mgmt Grp Ltd Liability Partnership owns 3.73 million shares for 0.09% of their portfolio. Cormorant Asset Limited Liability holds 275,000 shares or 4.79% of its portfolio. Aqr Mngmt Limited Liability Co reported 0% in bluebird bio Inc (NASDAQ:BLUE). Woodstock has invested 0.19% in bluebird bio Inc (NASDAQ:BLUE). Winslow Evans And Crocker, a Massachusetts-based fund reported 2,900 shares. Glob X Ltd Liability stated it has 180 shares. Bank & Trust Of America De invested in 84,403 shares.

The stock of bluebird bio Inc (NASDAQ:BLUE) hit a new 52-week high and has $182.68 target or 9.00 % above today’s $167.60 share price. The 7 months bullish chart indicates low risk for the $7.68 billion company. The 1-year high was reported on Nov, 21 by Barchart.com. If the $182.68 price target is reached, the company will be worth $691.20 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 52,820 shares traded. bluebird bio Inc (NASDAQ:BLUE) has risen 112.34% since November 21, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.

Analysts await bluebird bio Inc (NASDAQ:BLUE) to report earnings on February, 28. They expect $-1.59 earnings per share, up 15.43 % or $0.29 from last year’s $-1.88 per share. After $-1.73 actual earnings per share reported by bluebird bio Inc for the previous quarter, Wall Street now forecasts -8.09 % EPS growth.

bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage

Among 23 analysts covering bluebird bio (NASDAQ:BLUE), 14 have Buy rating, 2 Sell and 7 Hold. Therefore 61% are positive. bluebird bio has $244 highest and $14 lowest target. $128.75’s average target is -23.18% below currents $167.6 stock price. bluebird bio had 67 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, June 3 by Cantor Fitzgerald. As per Friday, August 28, the company rating was maintained by Roth Capital. BTIG Research maintained bluebird bio Inc (NASDAQ:BLUE) on Thursday, August 3 with “Hold” rating. Morgan Stanley downgraded it to “Equal-Weight” rating and $69 target in Monday, December 7 report. On Friday, June 16 the stock rating was downgraded by Standpoint Research to “Reduce”. SunTrust maintained it with “Buy” rating and $163 target in Friday, November 3 report. The company was maintained on Wednesday, June 14 by Morgan Stanley. The company was upgraded on Friday, November 3 by Morgan Stanley. The rating was maintained by Leerink Swann with “Buy” on Wednesday, November 1. The firm has “Buy” rating by Cowen & Co given on Tuesday, June 6.

More important recent bluebird bio Inc (NASDAQ:BLUE) news were published by: Nasdaq.com which released: “Bluebird Bio Inc. (BLUE) Has Surged To A New High After Q3 Report” on November 01, 2017, also Nasdaq.com published article titled: “Why Earnings Season Could Be Great for bluebird bio (BLUE)”, Businesswire.com published: “Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell …” on November 16, 2017. More interesting news about bluebird bio Inc (NASDAQ:BLUE) was released by: Businesswire.com and their article: “bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 …” with publication date: November 16, 2017.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company has market cap of $7.68 billion. The Firm is focused on developing gene therapies for severe diseases and cancer. It currently has negative earnings. With its lentiviral gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: